AvenCell Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing next-generation CAR-T cell therapies for hard-to-treat cancers, particularly hematological malignancies like acute myeloid leukemia (AML).[1][2][3][5] It builds autologous and allogeneic switchable CAR-T products using proprietary Universal Switchable CAR technology from GEMoaB (now AvenCell Europe GmbH) combined with Intellia's CRISPR/Cas9 platform, targeting antigens like CD123 for relapsed/refractory AML (AVC-101 autologous, AVC-201 allogeneic) and expanding to B-cell lymphomas (AVC-203).[1][2][4][5][7] These therapies address limitations of current CAR-T by improving safety, persistence, therapeutic window, and scalability through switchable control and rejection-resistant allogeneic cells, serving patients with unmet needs in oncology.[1][3][5] Backed by $250 million initial capital from Blackstone and a $112 million Series B led by Novo Holdings in 2024, plus up to $40 million AMED grant, AvenCell shows strong growth with ongoing trials and pipeline advancement.[1][4][5][7]
AvenCell was launched in 2021 by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics, incorporating the clinical-stage GEMoaB GmbH (rebranded AvenCell Europe GmbH) based in Dresden, Germany.[1][4][5] The idea emerged from merging GEMoaB's switchable universal T-cell technology with Intellia's CRISPR/Cas9 allogeneic platform to overcome CAR-T limitations like manufacturing scalability and tumor applicability.[1][2][4] Headquartered in Watertown, Massachusetts, with R&D in Germany and a Japan subsidiary, early traction included advancing AVC-101 and AVC-201 into clinical trials for AML, demonstrating encouraging safety and efficacy.[5][7] Leadership features experts like President & CEO Andrew Schiermeier, Ph.D., and manufacturing head Marc with 20+ years in CAR-T.[1][7]
AvenCell rides the cell therapy wave, addressing CAR-T shortcomings in persistence, safety, and solid tumor efficacy amid a market projected for explosive growth in oncology immunotherapies.[1][2][3] Timing aligns with maturing CRISPR tools and regulatory nods for allogeneic approaches, fueled by high unmet needs in relapsed/refractory AML and lymphomas where options are limited.[5][7] Favorable forces include non-dilutive grants like AMED's $40 million and VC influx (Novo Holdings, F-Prime), enabling global trials in the US, Europe, and Japan.[2][5][7] It influences the ecosystem by pioneering "first-of-its-kind" universal, switchable platforms, potentially shifting manufacturing paradigms and expanding adoptive cell therapy to broader cancers.[1][2][6]
AvenCell is poised to disrupt cell therapy with near-term milestones like AVC-201 dose-escalation data, AVC-203 lymphoma trials, and additional pipeline entries over the next two years.[5][7] Trends like advanced gene editing, combo therapies, and autoimmune expansions will shape its path, bolstered by strong funding and KOL collaborations.[5][7] Its influence may evolve from AML focus to paradigm leader in scalable, controllable CAR-T, delivering the "future of cell therapy" as its name evokes—if clinical persistence holds.[2][6] This positions AvenCell to transform hard-to-treat cancer care, building on its mission-driven origins.[1][3]
AvenCell has raised $110.0M in total across 1 funding round.
AvenCell's investors include F-Prime Capital Partners.
AvenCell has raised $110.0M across 1 funding round. Most recently, it raised $110.0M Series B in October 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2024 | $110.0M Series B | F-Prime Capital Partners |
